A meta-analysis helps to clarify the usefulness of gliflozins in the treatment of type II diabetic patients with atherosclerotic disease or risk factors
pp 74-83
Downloads
Published
2025-05-07
Issue
Section
OUTSTANDING PUBLICACIONES
License
Copyright (c) 2025 Argentine Journal of Cardiology

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.







